Following the 2024 American Academy of Dermatology (AAD) meeting in San Diego, a new report on various skin diseases, including data on conditions such as psoriasis, atopic dermatitis (AD), and hidradenitis suppurativa (HS), will be published. Several new studies regarding the treatment have been published.
In the latest interview, HCP Live The team from Raj Chobatiya, MD, MSCI, FAAD, associate professor at Rosalind Franklin University of Chicago Medicine and founder and director of the Medical Dermatology and Immunology Research Center, will highlight key data highlighted in the AAD. He gave a lecture on some of the topics and also described his own data. Their take on the findings.
First, Dr. Chovatiya was asked about new 52-week data presented at a conference on oral upadacitinib for the treatment of non-segmental vitiligo.
“There is another exciting moment in the development of treatments for vitiligo, in part because we are pushing JAK inhibitors beyond topical treatments for this disease. ” said Chovatiya. “So, of course, topical ruxolitinib has been a very important game-changing drug for this disease. But the problem has always been for people who have a large body surface area or who can't really apply the cream every day. ”Given the fact that treatments and pigmentation treatments take years and results are slow, could oral molecules do the heavy lifting? ”
This is where new data for upadacitinib comes in, he noted. Chovatiya explained that after a year, clinicians will be able to actually help patients see higher levels of repigmentation not only in the facial area, but also in hard-to-repigment areas around the body. did.
Chobatiya was then asked about the significance of the Tapinarov data on the pigmented skin atopic dermatitis patient cohort. He himself was a co-author of the study.
“When it came to the Tapinarov treatment, the results were similar across all the different socio-demographic variables analyzed, and even for light and dark skin tones. This is in line with what we have seen from other treatments. That definitely suggests that's the case with Tapinarov,'' Chobatiya said. “But importantly, this was one of the most diverse trials we have recently experienced, with a very high proportion of individuals identifying as having diverse skin types.”
Dr. Chovatiya said the significance of this study is that it represents some of the more “strong” data on the drug, and that baseline and treatment scores can change based on an individual's perception of erythema, hyper-erythema. He pointed out that one thing is to formally communicate what is known to dermatologists to the research team. and hypopigmentation.
Finally, Dr. Chovatiya was asked about the newly published phase 2 data on lutikizumab for HS.
“This is exciting because any drug that is better than a placebo is exciting in the HS world,” he said. “This is extremely difficult to do, given that many trials have failed to do so successfully due to a variety of factors: unpredictable placebo rates, highly ebb and flow diseases, The question is whether we're looking at the right endpoints at the right time. So it's very important to think about drugs that may be acting on the early underlying cytokines that are so important in many inflammations and diseases. I'm particularly interested in what the possibilities are if this moves into a third stage.”
For more on Chovatiya's take on the data presented at AAD, read the full interview above.
The quotes in this summary have been edited for clarity.